Larvol Delta - Alzamend-Neuro-Partners-With-the-Miller-School-of-Medicine-Interdisciplinary-Stem-Cell-Institute-at-the-University-of-Miami-for-ALZN002-Phase-IIIA-Immunotherapy-Vaccine-Clinical-Trial-to-Treat-Mild-to-Moderate-Dementia-of-the-Alzheimers-Type

LISPRO (lithium/proline/salicylate) - Alzamend Neuro

ALZN002 - Alzamend Neuro

https://www.businesswire.com/news/home/20221228005104/en/Alzamend-Neuro-Partners-With-the-Miller-School-of-Medicine-Interdisciplinary-Stem-Cell-Institute-at-the-University-of-Miami-for-ALZN002-Phase-IIIA-Immunotherapy-Vaccine-Clinical-Trial-to-Treat-Mild-to-Moderate-Dementia-of-the-Alzheimer%E2%80%99s-Type

Dec 28, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next